Lupin on Friday said it has received an establishment inspection report from the United States Food and Drug Administration for its Nagpur facility in Maharashtra. The inspection was conducted between August 5-8, Lupin said. The inspection for the oral solid facility closed without any Form 483 observation, it added. The Nagpur facility is the company’s largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance, Lupin said.